Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Brooklyn Immunotherapeutics : to Transfer Share Listing to Nasdaq From NYSE American

10/15/2021 | 10:49am EST


ę MT Newswires 2021
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
11/23BROOKLYN IMMUNOTHERAPEUTICS, INC. : Other Events (form 8-K)
AQ
11/19Brooklyn ImmunoTherapeutics Plans Secondary Offering Of 6.28 Million Shares
MT
11/19Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Sec..
AQ
11/12FALSE12-312021Q300007485920.50.50000 : CommonClassAMember2020-12-310000748592btx:CommonUni..
AQ
11/12BROOKLYN IMMUNOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exh..
AQ
11/09Earnings Flash (BTX) BROOKLYN IMMUNOTHERAPEUTICS LLC Posts Q3 Loss $-1.70
MT
10/26BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA : BTX) added to NASDAQ Composite Index
CI
10/15BROOKLYN IMMUNOTHERAPEUTICS : to Transfer Share Listing to Nasdaq From NYSE American
MT
10/14BROOKLYN IMMUNOTHERAPEUTICS : to Move Stock Exchange Listing to Nasdaq - Form 8-K
PU
10/14BROOKLYN IMMUNOTHERAPEUTICS : to Move Stock Exchange Listing to Nasdaq
AQ
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Capitalization 321 M 321 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 10
Free-Float 47,4%
Chart BROOKLYN IMMUNOTHERAPEUTICS, INC.
Duration : Period :
Brooklyn ImmunoTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BROOKLYN IMMUNOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 6,16 $
Average target price 20,00 $
Spread / Average Target 225%
EPS Revisions
Managers and Directors
Howard J. Federoff President, Chief Executive Officer & Director
Sandra Gurrola Chief Financial Officers
Charles R. Cherington Chairman
Kevin A. D'Amour Chief Scientific Officer
Jay Sial Chief Administrative & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
BROOKLYN IMMUNOTHERAPEUTICS, INC.37.50%321
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431